NCT02567695View on ClinicalTrials.gov

A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Sickle Cell Disease
Interventions
DRUG

GBT440

Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)

Trial Locations (1)

78209

ICON Early Phase Services, LLC Clinical Research Unit, San Antonio

Sponsors
All Listed Sponsors
lead

Global Blood Therapeutics

INDUSTRY

NCT02567695 - A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects | Biotech Hunter | Biotech Hunter